Lilly Announces Webcast to Provide Alzheimer's Disease Update at AAIC

Rhea-AI Summary

Eli Lilly and Company will host a webcast on July 17, 2023 at the Alzheimer's Association International Conference. The webcast will focus on results from the donanemab TRAILBLAZER-ALZ 2 clinical trial and the broader landscape in Alzheimer's disease. A live audio webcast will be available on Lilly's Investor website and a replay will be available for 90 days.

INDIANAPOLIS, July 11, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will host a webcast on Monday, July 17, 2023 at the Alzheimer's Association International Conference. The webcast will begin at 1:30 p.m. Eastern time, and remarks will primarily focus on results from the donanemab TRAILBLAZER-ALZ 2 clinical trial, as well as the broader landscape in Alzheimer's disease.

A live audio webcast will be available on the "Webcasts & Presentations" section of Lilly's Investor website at https://investor.lilly.com/webcasts-and-presentations. A replay of the presentation will be available on this same website for approximately 90 days.

About Lilly
Lilly unites caring with discovery to create medicines that make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help more than 51 million people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges, redefining diabetes care, treating obesity and curtailing its most devastating long-term effects, advancing the fight against Alzheimer's disease, providing solutions to some of the most debilitating immune system disorders, and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/newsroom or follow us on Facebook, Instagram, Twitter and LinkedIn. F-LLY

Refer to:	Jordan Bishop; jordan.bishop@lilly.com; 317-473-5712 (Media)
	Joe Fletcher; jfletcher@lilly.com; 317-296-2884 (Investors)

 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/lilly-announces-webcast-to-provide-alzheimers-disease-update-at-aaic-301873440.html

SOURCE Eli Lilly and Company

FAQ

When is Eli Lilly and Company hosting a webcast?

Eli Lilly and Company is hosting a webcast on July 17, 2023.

What is the focus of the webcast?

The webcast will primarily focus on results from the donanemab TRAILBLAZER-ALZ 2 clinical trial and the broader landscape in Alzheimer's disease.

Where can I access the live audio webcast?

The live audio webcast will be available on Lilly's Investor website at https://investor.lilly.com/webcasts-and-presentations.

How long will the replay of the presentation be available?

The replay of the presentation will be available on the same website for approximately 90 days.